Gain insights and perspectives from this multidisciplinary panel of experts as they discuss cases and explore strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma. This distinguished Virtual Tumor Board features Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center. Start the activity now!

In this case-based activity on pathology and oncology perspectives in triple-negative breast cancer (TNBC), Dr. Ira Bleiweiss and Dr. Sara Tolaney will provide expert insight into the roles of receptor and expression status in prognostication and treatment selection, pathological characteristics of different subtypes, incorporation of shared goals and biomarker testing into therapeutic selection, and strategies for recognizing and mitigating adverse events. Start the activity now!

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non–small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!

Gain insight and expertise in this discussion on acquired thrombotic thrombocytopenic purpura. Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, will provide guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP. Start the activity now!

In this activity, hear about the latest data and strategies for hitting the target in HER2-positive metastatic colorectal cancer. Dr. Christopher Lieu, Associate Professor at the University of Colorado Cancer Center, explores actionable targets to inform personalized care plans, guideline-recommended combination and sequencing strategies, adverse event monitoring and management, and more. Start the activity now!

In this activity, discover new insights and real-world evidence for improved patient outcomes in recurrent/metastatic head and neck squamous cell carcinoma from Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine at the University of California, San Diego Health. Learn about differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, impacts on quality of life, and more. Start the activity now!

In this Virtual Tumor Board, discover strategies for building comprehensive care plans for patients with esophagogastric cancers from Dr. Jaffer Ajani, Professor of Gastrointestinal Medical Oncology at MD Anderson Cancer Center; Dr. Lei Zhao, Assistant Professor of Pathology at Brigham and Women's Hospital; and Dr. Kelley Rone, Advanced Practice Nurse in Gastrointestinal Oncology at the Mayo Clinic. Start the activity now to hear their case-based discussion for the multidisciplinary team!

In this session, Constance Visovsky, PhD, RN, ACNP, FAAN, Director and the Lewis & Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida, will clarify the mechanism by which CDK4/6 inhibitors in combination with endocrine therapy are thought to overcome resistance to endocrine therapy in ER-positive metastatic breast cancer, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting, as well as early and aggressive identification of side effects to minimize toxicity.

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, will explore the uses of immune checkpoint inhibition, a therapeutic strategy which is moving to earlier settings in breast cancer, including preoperative therapy with pembrolizumab/chemotherapy. The discussion will include an overview of immune-mediated adverse events and how they can be graded and managed. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer. She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explore the role of PI3K inhibitors for patients with a mutation in PIK3CA nd HR-positive, HER2-negative breast cancer, including alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents. Start the activity now!

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review the current options for treatment of HER2-positive breast cancer using HER2-targeted monoclonal antibodies, including the advantages and disadvantages regarding the combination of trastuzumab/pertuzumab/hyaluronidase, the indications for margetuximab, and the latest guidance on managing cardiac and other adverse events with HER2-targeted monoclonal antibody therapy. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. She will also highlight the differing considerations for management of patients taking these drugs. Start the activity now!

This case-based discussion brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.

VTE is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death. This online activity reviews signs and symptoms, risk assessment, and supportive care interventions.

Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity.

This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.